# Belimumab Treatment for IgG4-related Disease

> **NCT04660565** · PHASE4 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 60 (estimated)

## Conditions studied

- IgG4-related Disease

## Interventions

- **DRUG:** Prednisone and Belimumab
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT04660565
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01
- **Primary completion:** 2022-12
- **Final completion:** 2023-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04660565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04660565, "Belimumab Treatment for IgG4-related Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04660565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*